Tocilizumab and sarilumab are interleukin-6 (IL-6) receptor blockers that WHO recommends for patients diagnosed with severe or critical COVID-19.* They should be administered by a healthcare worker in a monitored clinical setting along with the current standard of care for COVID-19, which includes oxygen, corticosteroids, and other medications.  Patients with non-severe COVID-19 should not be given this treatment.*A patient has severe COVID-19 when they have signs of pneumonia, severe respiratory distress, and their blood oxygen level is low. A patient has critical COVID-19 when the need life sustaining treatment, have acute respiratory distress syndrome, or have septic shock (evidence of injury to other organs). More.
